Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ichiro Yoshimoto to Become New President of CMIC
September 4, 2014
- CMIC Holdings to Boost Domestic CSO Business, Converting Its Subsidiary to JV with UDG Healthcare
September 4, 2014
- Drug Price Settlement Rate Might Hit 70% in September: Wholesaler Exec
September 3, 2014
- Daiichi Sankyo Espha to Launch AG Versions of Cravit after NHI Price Listing in December
September 3, 2014
- Ono Launches Opdivo, Making Full-Fledged Entry to Oncology Field
September 3, 2014
- Eisai Books 18.7 Billion Yen in Payments to Medical Institutions in FY2013
September 2, 2014
- Astellas’ FY2013 Funding to Medical Institutions Totals 18.7 Billion Yen
September 2, 2014
- 33.2 Billion Yen Paid to Medical Institutions in FY2013: Daiichi Sankyo
September 2, 2014
- Takeda’s Payments to Health Professionals Down 30% in FY2013
September 2, 2014
- Kyowa Kirin Initiates PIIb Study of Regpara Successor in Japan
September 2, 2014
- Kyowa Kirin Merges Ethics Office into CSR Promotion Dept., Following Improper Involvement of Its Employees in Clinical Study
September 2, 2014
- 10-Year Epidemiology Study Finds No Significant Increase in Bladder Cancer Risk from Actos: Takeda
September 1, 2014
- Novartis Pharma Submits Improvement Plan, Notifies of Over 2,500 Unreported Serious ADRs
September 1, 2014
- Mundipharma Begins PII Trial on Antifolate Pralatrexate in Japan
September 1, 2014
- Daiichi Sankyo Forms Sales Agreement with Kaketsuken for Hepatitis B Vaccine
September 1, 2014
- Fujifilm Starts PI Study of Its Anticancer Agent FF-10501 for Hematological Malignancy in US
September 1, 2014
- Kracie Poised to Re-Enter New Drug Biz with Scabies Treatment
August 29, 2014
- Chugai Provided 17.3 Billion Yen to Healthcare Professionals in 2013, Down 4% from 2012
August 29, 2014
- Sanofi Greater China Head Baschiera to Shepherd Japan Unit
August 29, 2014
- Roche Obtains First Refusal Right for All Chugai’s Products with Partial Amendment to Strategic Alliance Deal
August 29, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…